Novo Nordisk A/S (NONOF)
| Market Cap | 227.37B |
| Revenue (ttm) | 49.11B |
| Net Income (ttm) | 17.49B |
| Shares Out | n/a |
| EPS (ttm) | 3.93 |
| PE Ratio | 13.00 |
| Forward PE | 12.16 |
| Dividend | 1.66 (3.30%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 1,605 |
| Average Volume | 768,351 |
| Open | 51.49 |
| Previous Close | 49.61 |
| Day's Range | 49.82 - 51.49 |
| 52-Week Range | 45.00 - 141.19 |
| Beta | 0.27 |
| RSI | 34.95 |
| Earnings Date | Aug 6, 2025 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsNews
Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
BENSALEM, Pa., Aug. 13, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit agai...
Novo Nordisk: The Falling Knife That Keeps Giving
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines – NVO
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such investors ar...
ATTENTION NYSE: NVO INVESTORS: Contact Berger Montague About a Novo Nordisk A/S Class Action Lawsuit
PHILADELPHIA , Aug. 12, 2025 /PRNewswire/ -- Berger Montague PC is investigating claims under the federal securities laws against Novo Nordisk A/S (NYSE: NVO) ("Novo" or the "Company"), a global pha...
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options
Hims & Hers Remains Outside Novo Nordisk's Growing Legal Storm For Now
Novo Nordisk filed more Wegovy lawsuits against smaller U.S. ... Full story available on Benzinga.com
Deadline Alert: Novo Nordisk A/S (NVO) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
LOS ANGELES, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming September 30, 2025 deadline to file a lead plaintiff motion in the class action filed on be...
UK Government, Eli Lilly Partner To Target Obesity Health Gaps
A new program to improve access to weight management services across the U.K. National Health Service (NHS) could benefit several obese patients . The initiative , announced Tuesday, combines governme...
Best Stock to Buy: Eli Lilly Stock vs. Novo Nordisk Stock
Investors have a tough choice between these two excellent companies.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Nordisk A/S Lawsuit - NVO
NEW YORK , Aug. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The ...
Novo Nordisk Stock: Buy or Sell?
News from a competitor is increasing enthusiasm for Novo Nordisk stock.
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES , Aug. 12, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo Nordisk" o...
Novo Nordisk A/S Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights – NVO
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed ...
Why is Novo Nordisk excluding Hims & Hers in its lawsuits over Wegovy copies?
In Novo Nordisk's legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug Wegovy, one name remains conspicuously absent: Hims & Hers. The high-profil...
Is the Market Bullish or Bearish on Novo Nordisk?
Novo Nordisk's (NYSE: NVO) short percent of float has fallen 7.89% since its last report. The company recently reported that it has 23.58 million shares sold short , which is 0.7% of all regular shar...
Deadline Alert: Novo Nordisk A/S (NVO) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming September 30, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors...
Novo Nordisk: Watching Value Investors Buy The Dip Hurts My Eyes
Novo Nordisk: Enough Is Enough
Industry Analysis: Pharmaceuticals Like Novo Nordisk Offer Long-Term Opportunities
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are a...
The Gross Law Firm Reminds Novo Nordisk A/S Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 30, 2025 - NVO
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class perio...
NVO Investors are Reminded of Final Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES , Aug. 11, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo" or "the Co...
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S (NYSE: NVO)
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquir...
As Novo Nordisk ramps up lawsuits over Wegovy copies, investors ask where is Hims?
In Novo Nordisk's legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug Wegovy, one name remains conspicuously absent: Hims & Hers.